Low-Dose DOACs Reduce VTE Risk in Transplant-Ineligible Multiple Myeloma: Insights from the BENEFIT Trial
Journal of Thrombosis and Haemostasis (JTH) has shared a post on LinkedIn:
“Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of the BENEFIT trial
In this phase 3 trial of 257 patients with transplant-ineligible newly diagnosed multiple myeloma, the 6-month cumulative incidence of VTE was 4.8%. Among prophylaxis strategies, low-dose DOACs significantly reduced VTE risk compared to heparin or aspirin. Proteinuria ≥0.44 g/L and monoclonal protein ≥22 g/L emerged as strong independent risk factors for VTE. Findings highlight DOACs as a potentially superior prophylaxis option in this high-risk population.”
Title: Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial
Authors: Emilie Chalayer, Corinne Frere, Elisabeth Daguenet, Thomas Lecompte, Bernard Tardy, Ilhame Bounouara, Manon Sapet, Arthur Bobin, Stephanie Harel, Olivier Decaux, Karim Belhadj, Cyrille Touzeau, Margaret Macro, Mohamad Mohty, Philippe Moreau, Jill Corre, Hervé Avet–Loiseau, Lionel Karlin, Thierry Facon, Aurore Perrot, Cyrille Hulin, Salomon Manier, Laurent Frenzel, Xavier Leleu
Read the full paper here.
Find similar posts on Hemostasis Today.
-
Oct 18, 2025, 16:59Raul Santos Gave 2 Talks at SAC 2025: On The Role of LDL-C and Future of Lipid-lowering Therapies
-
Oct 18, 2025, 16:57Marilena Vrana: What An Inspiring Week at The 2025 Plasma Protein Forum and Business Forum
-
Oct 18, 2025, 16:53Caitlin Raymond: When Technology Meets Physiology in Neonatal Patients
-
Oct 17, 2025, 08:37Salome Mekhuzla Invites You to Join WHO Essential Medicines List 2025 Updates Webinar on Hemophilia and VWD
-
Oct 17, 2025, 08:36Plasma Protein Forum 2025: From Anti-D Plasma and Blood Supply Incentives to the Future of AI
-
Oct 18, 2025, 16:56Alexandra Whiteside on Improving Coagulation Kinetics
-
Oct 18, 2025, 16:52Wolfgang Miesbach on Differential Diagnosis of Thrombocytopenia
-
Oct 18, 2025, 16:49Arisa Chuklin, Thita Joy Chiasakul, and Noppacharn Uaprasert on Management of Thrombosis in Behçet’s Syndrome
-
Oct 18, 2025, 16:47State of the Art Review On Angina After PCI From Javier Escaned's Team
-
Oct 18, 2025, 16:25Luciana Werneck Zuccherato and Colleagues on A3 domain of FVIII in Severe Hemophilia A
-
Oct 16, 2025, 06:07ClearPlasma - A New Breakthrough in Stopping Life-Threatening Bleeds
-
Oct 14, 2025, 05:26Ryan C. Heniford: Every Thrombus Prevented Is a Patient Protected
-
Oct 13, 2025, 04:48Archil Jaliashvili showcases how BHOC builds on Hemopure’s success to revolutionize surgery and care
-
Oct 13, 2025, 02:46Flora Peyvandi: First Proposed Blood Test for Chronic Fatigue Syndrome - What Scientists Think
-
Oct 13, 2025, 02:44Silvio Maresca: Honored to be part of this international research project - ThrombUS+
-
Oct 18, 2025, 16:55Emilia Arturo: Your Reminder to Donate Blood If You Can, When You Can
-
Oct 18, 2025, 16:51Allison Wheeler Rallies Support for Magdalena Lewandowska's NYC Marathon Run Benefiting NBDF
-
Oct 17, 2025, 16:07WFH Volunteer Mary Byrne Transforms Bleeding Disorder Diagnostics
-
Oct 17, 2025, 08:52Erica Sparkenbaugh: Shout Out to My Doctoral Student Kylie Hutchison for Her Outstanding Oral Presentation
-
Oct 17, 2025, 08:45Shamee Shastry Shares Lean and Six Sigma in Transfusion Medicine Training Program's Success